Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
26 Cards in this Set
- Front
- Back
- 3rd side (hint)
Name the 4 interferon alpha
and give their common structural feature |
2a (Roferon®-A)
2b (Intron® A) n1 (Wellferon®) n3 (Alferon® N) Recombinant human Interferon Alpha |
|
|
FDA-approved indications of
Interferon alpha 2a (Roferon®-A) 2b (Intron® A) n1 (Wellferon®) n3 (Alferon® N) |
FDA-approved indications
Hairy cell leukemia AIDS-related Kaposi's sarcoma chronic myelogenous leukemia (CML) Chronic hepatitis B and C genital warts papillomavirus |
|
|
What are remarkable features of
Interferon alpha 2a (Roferon®-A) HINT: MAJOR ADVERSE REACTIONS 2b (Intron® A) n1 (Wellferon®) n3 (Alferon® N) |
Major adverse reactions are fever,
myalgia headache; i.e., flu-like symptoms. |
|
|
Name:
a. an interferon alfacon-1 b. its structural feature c. FDA approved indications |
a. Infergen®
b. Consensus alpha interferon c. Chronic Hepatitis C |
|
|
Remarkable fact of Interferon alfacon-1,Infergen®?
HINT: ONE OF ITS KIND |
The first second generation interferon
|
|
|
Name:
a. the 2 Peginterferon alfa b. their structural feature c. FDA approved indication |
a. 2a (Pegasys)
2b (PEG-INTRON) b. Pegylated recombinant human interferon alpha c. FDA approved indications: Chronic hepatitis C alone or with ribavirin |
|
|
Remarkable feature of Peginterferon alfa:
2a (Pegasys) 2b (PEG-INTRON) HINT: Benefits of pegylation |
Pegylation allows once/week dosing
|
|
|
Name the 3 interferons that treat Chronic hepatitis C
|
Interferon alfacon-1
(Infergen) Peginterferon alfa 2a (Pegasys) 2b (PEG-INTRON) |
|
|
Name:
a. the 4 interferon beta drugs b. their structural feature c. FDA approved indication |
a.1b (Betaseron®, Extavia®)
1a (Avonex®, Rebif®) b. recombinant human interferon beta c. Tx of relapsing, remitting MS and 2ndary MS |
|
|
Remarkable feature interferon beta drugs
1b (Betaseron®, Extavia®) 1a (Avonex®, Rebif®) HINT: 1. DOSAGE FORM 2. ADVERSE REACTIONS |
Form: single-use, pre-filled syringes
Adverse reactions: flu-like symptoms |
|
|
Name:
a. the 1 interferon gamma-1-b drug: b. its structural feature c. FDA approved indication |
a. Actimmune
b. recombinant human interferon gamma c. Reduces frequency/severity of infections associated with chronic granulomatous disease; delays disease progression in severe, malignant osteopetrosis |
|
|
Remarkable features of Interferon gamma-1-b, Actimmune?HINT: Administration
|
Administered SQ three times weekly at 50 μg/m2
|
|
|
Name:
a. a recombinant human interleukin-2 drug b. its FDA approved indication |
a. Aldesleukin (Proleukin)
b. metastatic malignant melanoma metastatic renal cell carcinoma |
|
|
Remarkable features of Aldesleukin (Proleukin)?
HINT: SEVERE ADVERSE REACTIONS |
Severe toxicity (capillary leak syndrome)
Cardiac arrythmias Myocardial Infarction respiratory failure GI bleeding Kidney failure |
|
|
Name:
a. thrombopoeitic growth factor, IL-11 b. its FDA approved indications |
a. Oprelvekin (Neumega)
b. Prevention of chemotherapy-associated thrombocytopenia |
|
|
Remarkable features of Oprevelkin (Neumega)?
HINT: ADMINISTRATION & DOSING |
Administer SQ 50mcg/kg every day for adults for 14-21 days
|
|
|
Name:
a. a selective interleukin 1- receptor antagonist b. its FDA approved indications |
a. Anakinra (Kineret)
b. Rheumatoid arthritis alone or with other DMARDs |
|
|
Remarkable features of Anakinra (Kineret), a selective interleukin 1-receptor antagonist?
HINT: ADMINISTRATION & DOSING |
Administer SQ 100 mg/day
monitor neutrophil count for 3 months |
|
|
Name:
a. a granulocyte colony stimulating factor b. its FDA approved indication |
a. Filgrastim (Neupogen)
b. Neutropenia in: chemotherapy bone marrow transplant other neutropenias |
|
|
Remarkable features of Filgastrim (Neupogen)?
HINT: EFFECTIVENESS |
Reduces
bacterial infection mortality, incidence duration of hospitalization. |
|
|
Name:
a. the modified Filgrastim b. its FDA approved indication |
a. Pegfilgrastim (Neulasta)
b. Decrease chemotherapy-associated neutropenia |
|
|
a. What would you use for myeloid reconstitution after chemotherapy and to promote bone marrow transplant?
Pegflgrastim (Neulasta) Sargramostin (Leukine/Prokine) Filgrastim (Neupogen) Romiplostim (Nplate) b. State the drug's structural feature |
a. Sargramostim (Leukine/Prokine)
b. granulocyte-macrophage colony stimulating factor |
|
|
Remarkable feature of Sargramostin (Leukine/Prokine)?
HINT: DOSING CONSIDERATIONS |
Half dose if:
neutrophil count <20,000 cells/cc & platelets <500,000/cc |
|
|
a. What would you use to treat chronic immune (idiopathic) thrombocytpenic purpura?
b. State why. (Structural feature of drug) |
a. Rominoplostim (Nplate)
b. thrombopoetin mimetic |
|
|
Remarkable features of Rominoplostim (Nplate)?
|
A peptibody consisting of IgG1 Fc fused to a peptide with 2 TPO receptor-binding domains
|
|
|
a. If you were an endurance athlete and wanted outdo your oponents during your next race, what drug would you try to get on the street market?
b. State why (Structural feature) |
a. Epoeitin alfa (Epogen)
First US biotechnology blockbuster drug b. cytokine that stimulates production of red blood cells. |
|